Welcome to our dedicated page for Anixa Biosciences news (Ticker: ANIX), a resource for investors and traders seeking the latest updates and insights on Anixa Biosciences stock.
Anixa Biosciences, Inc. (NASDAQ: ANIX) is a clinical-stage biotechnology company whose news flow centers on the treatment and prevention of cancer. Company announcements frequently highlight progress in its ovarian cancer immunotherapy program and its portfolio of cancer vaccines, especially an investigational breast cancer vaccine developed in collaboration with Cleveland Clinic.
News items for ANIX often cover clinical trial milestones, such as completion of a Phase 1 trial, presentation of final data at major scientific meetings, and plans to advance programs into subsequent phases of development. For the breast cancer vaccine targeting α-lactalbumin, disclosures have included safety and immune response findings, details on trial cohorts, and steps to transfer the related IND sponsorship from Cleveland Clinic to Anixa for future trials.
Another recurring theme in Anixa’s news is its ovarian cancer CER-T (CAR-T) program, including regulatory and naming milestones. The company has reported that the World Health Organization’s International Nonproprietary Names Expert Committee approved “liraltagene autoleucel” (lira-cel) as the non-proprietary name for its FSHR-targeted CAR-T therapy, and updates often describe the ongoing first-in-human trial in recurrent ovarian cancer.
Investors and observers can also expect intellectual property updates, such as U.S. and international patent issuances that extend protection for the breast cancer vaccine technology, as well as participation in investor conferences and research-focused fireside chats. Together, these news items provide insight into Anixa’s clinical progress, collaboration activities with institutions like Cleveland Clinic and Moffitt Cancer Center, and the evolution of its immuno-oncology pipeline.
Anixa Biosciences, Inc. (NASDAQ: ANIX) announced Dr. Jose Conejo-Garcia will present at the Rivkin Center and the American Association for Cancer Research (AACR) 14th Biennial Ovarian Cancer Research Symposium on September 28, 2022. He will discuss the company's ovarian cancer CAR-T technology, targeting follicle-stimulating hormone receptors on ovarian granulosa cells. The ongoing Phase 1 clinical trial has successfully treated its first patient, potentially transforming ovarian cancer treatment. Anixa collaborates with Moffitt Cancer Center on this innovative approach.
Anixa Biosciences, Inc. (NASDAQ: ANIX) announced its participation in the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022. This hybrid event will include a presentation detailing Anixa's recent corporate achievements, including the treatment of the first patient in its CAR-T based ovarian cancer clinical trial. The on-demand presentation will begin at 7:00 a.m. ET on September 12, 2022, with a replay accessible for 90 days. Anixa focuses on cancer and infectious disease therapies and collaborates with top research institutions.
Anixa Biosciences, Inc. (NASDAQ: ANIX) has initiated treatment for the first patient in a Phase 1 clinical trial of its chimeric antigen receptor T-cell (CAR-T) therapy aimed at ovarian cancer, in partnership with Moffitt Cancer Center. The trial will assess the safety and efficacy of the therapy targeting the follicle stimulating hormone receptor (FSHR), which is selectively expressed on ovarian cells. A total of up to 48 patients will participate in the study, with hopes that the unique targeting approach can enhance treatment effectiveness for challenging solid tumors.
Anixa Biosciences, Inc. (NASDAQ: ANIX) announced a Notice of Allowance from the U.S. Patent and Trademark Office regarding its breast cancer vaccine technology. This notice broadens intellectual property protection for the vaccine, which aims to prevent Triple Negative Breast Cancer (TNBC). Developed in collaboration with Cleveland Clinic, the vaccine is currently in Phase 1 clinical trials, with preliminary results expected by year-end. The technology leverages a breast-specific protein, α-lactalbumin, to stimulate immune protection against certain breast tumors.
Anixa Biosciences, Inc. (NASDAQ: ANIX) announced the publication of a peer-reviewed article in Clinical and Experimental Vaccine Research, detailing preclinical studies on a novel ovarian cancer vaccine technology using AddaVax adjuvant. The study indicates that the vaccine targets the anti-Müllerian hormone receptor 2, potentially preventing ovarian cancer—a challenging malignancy. Anixa's CEO stated that clinical development is ongoing, backed by the National Cancer Institute's PREVENT Program. This technology represents a significant advancement in cancer prevention.
Anixa Biosciences, Inc. (NASDAQ: ANIX) will present a company update at the H.C. Wainwright Global Investment Conference from May 23-26, 2022. The presentation will cover Anixa's recent achievements, including the initiation of a clinical trial for its CAR-T based ovarian cancer treatment. The on-demand presentation starts at 7:00 a.m. ET on May 24, 2022, and can be accessed through a provided webcast link. A replay will be available for 90 days. Anixa focuses on cancer therapies and infectious diseases, collaborating with top medical institutions to develop innovative treatments.
Anixa Biosciences (NASDAQ: ANIX) announced a presentation of its breast cancer vaccine trial at the ASCO Annual Meeting on June 3-7, 2022. The presentation, led by Dr. George Thomas Budd of Cleveland Clinic, focuses on a Phase 1 trial of an alpha-Lactalbumin vaccine for patients with operable triple-negative breast cancer (TNBC). With TNBC being a significant challenge in oncology, accounting for a high percentage of breast cancer deaths, Anixa’s approach targets proteins unique to this cancer type. The vaccine aims to activate the immune system for early tumor prevention.
On April 6, 2022, Anixa Biosciences (NASDAQ: ANIX) announced that Dr. José Conejo-Garcia will present its ovarian cancer CAR-T technology at The 4th International Workshop on CAR-T on April 29, 2022. He will chair a panel discussing Chimeric Endocrine Receptor T-cell (CER-T) technology for treating ovarian cancer. A Phase 1 clinical trial using this innovative therapy has recently begun at Moffitt Cancer Center. Anixa holds an exclusive worldwide license for this technology.
Anixa Biosciences (NASDAQ: ANIX) has launched a Phase 1 trial for its innovative chimeric endocrine receptor T-cell (CER-T) therapy targeting ovarian cancer at Moffitt Cancer Center. This trial aims to assess the safety and effectiveness of CER-T therapy, which uniquely targets the follicle stimulating hormone receptor (FSHR), exclusively expressed on ovarian cells. With an exclusive license for this technology developed at the Wistar Institute, Anixa partners with leading scientists to enhance treatment options for recurrent, chemo-resistant ovarian cancer, potentially revolutionizing therapy for solid tumors.
Anixa Biosciences, Inc. (NASDAQ: ANIX) announced its participation in the 2022 Virtual Growth Conference hosted by M-Vest from March 28-30, 2022. The presentation will be led by Mike Catelani, the Chief Operating Officer and Chief Financial Officer, who will provide an overview of the company's business and program updates. Anixa focuses on developing cancer treatments and vaccines, including an innovative CAR-T immunotherapy and vaccines targeting triple negative breast cancer and ovarian cancer. For more details, visit www.anixa.com.